Paradigm Peptides

Overview

Paradigm Peptides is a US-based vendor founded in 2014, headquartered in Illinois, selling peptides, SARMs, nootropics, and research chemicals. The company has one of the longest operating histories among active grey-market vendors and maintains an A+ BBB rating. However, the company experienced a concerning shutdown in March 2024 before reopening, and its quality control documentation has gaps that prevent a higher grade despite strong Finnrick test results on specific products.

What We Found

Testing & Quality (Score: 60/100)

Finnrick Analytics tested 6 samples of Retatrutide from Paradigm Peptides between July and September 2025, awarding a confident Finnrick A rating (“Great”) — average score above 7.0, no score below 6.0. This is strong performance for a tested product.

However, Finnrick data is limited to a single product (Retatrutide). For the broader catalog — BPC-157, TB-500, SARMs, nootropics — no independent Finnrick testing data exists. The company claims 98%+ purity across products but does not publicly post COAs or lab reports on their website. Multiple reviewers confirm that HPLC/mass spectrometry data is not accessible without specific request, and even then availability is inconsistent.

One BBB reviewer reported sending a purchased product to independent testing and receiving results showing epistane (a prohormone) rather than the purchased compound — a serious adulteration allegation. The company disputed this claim.

Transparency (Score: 45/100)

No publicly accessible COA archive. Lab reports reportedly available on request but not standard practice. Manufacturing partnerships reference domestic US sources and some international sourcing, but specific partners and labs are not disclosed. The March 2024 shutdown (initially described as “maintenance”) with no public explanation raised transparency concerns.

Pricing (Score: 65/100)

Competitive pricing relative to market. BPC-157 at approximately $48/5mg or $144/15mg — lower than premium vendors like Peptide Sciences. SARMs sold in capsule form, which the company claims improves dosing consistency. Frequent discount codes and seasonal promotions.

Reputation (Score: 55/100)

• BBB: A+ rating (accredited), though individual reviews include serious allegations (product adulteration, broken vials with no resolution)
• Reddit: Mixed — some users report suspected product substitution (“Rad140 felt like dbol”), others praise quality
• Multiple review sites: Generally positive but many are affiliate-driven
• The March 2024 shutdown followed by return creates uncertainty about operational stability

Compliance (Score: 55/100)

Standard “research use only” disclaimers. BBB accreditation demonstrates some commitment to dispute resolution. Products sold in capsule/tablet form for SARMs — which some market observers note makes “research only” claims more difficult to sustain (individual dosing implies human consumption intent). No known FDA enforcement actions.

The PeptideExaminer Verdict

Paradigm Peptides benefits from a decade of operations, strong Finnrick testing on Retatrutide, competitive pricing, and BBB accreditation. But the lack of public COAs across most products, the serious adulteration allegation (even if disputed), and the unexplained 2024 shutdown create uncertainty. The A rating on Retatrutide is genuinely encouraging but represents one product out of a large catalog. More independent testing data across product lines would meaningfully improve confidence.

Grade: C+

Category	Score	Weight	Weighted
Transparency	45	20%	9.0
Testing	60	25%	15.0
Pricing	65	15%	9.75
Reputation	55	20%	11.0
Compliance	55	20%	11.0
Total			55.75 → C+

Sources: Finnrick Analytics (finnrick.com), BBB.org, Trustpilot, Reddit (r/sarmssourcetalk), SARMguide, Muscle and Brawn